№ lp_1_2_20143
File format: docx
Character count: 6250
File size: 69 KB
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical benefits, chemotherapy, PBS
Document Type:
FAQ
Organization:
Pharmaceutical Benefits Scheme
Author:
Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience:
Healthcare providers, prescribers, patients
Effective Period:
From December 1, 2024
Approval Date:
Not specified
Modification Date:
Not specified
Contextual Description:
FAQ document providing detailed information on the changes in PBS listing for Opdualag and Vyxeos under the EFC Program, including prescription and claiming details.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Caregiver Agreement Form
Program:
Enhanced Foster Care (EFC)
Service Type:
Family-Based Foster Care Treatment Service
Related System:
MiSACWIS
Subject:
Child Eligibility for Enhanced Foster Care Services
Participants:
Identified Caregiver(s), Assigned Foster Care Agency, EFC Clinical Case Manager, EFC Supervisor, PAFC Director
Required Information:
Child Name, Date of Birth, MiSACWIS Person ID, Caseworker, Foster Parent Name and Address
Content Elements:
Caregiver Qualifications, Completed Training, Scheduled Training, Transition Plan, Behavior Management Techniques, Service Level Engagement, Educational Participation, Crisis Management Tasks
Compensation Basis:
Daily Rate Above Standard Determination of Care
Rate Levels:
Level I, Level II, Level III, Adapted Rate
Signatures Required:
EFC Clinical Case Manager, Caregiver(s), EFC Supervisor, PAFC Director (if waiver required)
Waiver Condition:
Exception Authorization or Confirmation of Pressley Ridge Treatment Parenting Model Completion
Target Population:
Children in General Foster Care with Intensive Behavioral or Emotional Needs
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2025
Region / City:
Canberra
Topic:
Medical Procedures, Oncology, Hematology
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
Canberra Health Services
Target Audience:
Healthcare professionals involved in chemotherapy administration
Effective Period:
Ongoing
Approval Date:
2025-01-01
Date of Changes:
2025-01-01
Year:
2023
Region / City:
Canberra
Topic:
Chemotherapy Care
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Melissa O’Brien, A/g ED of CAS
Target Audience:
Clinical staff providing care to adult patients receiving chemotherapy
Effective Date:
24/04/2023
Amendment Date:
24/04/2023
Year:
2021
Region / city:
Australia
Topic:
Pharmaceutical Drug Submission
Document type:
Resubmission Request
Organization / institution:
PBAC
Author:
AbbVie Pty Ltd.
Target audience:
Healthcare professionals, PBAC
Validity period:
Not specified
Approval date:
2021
Date of amendments:
Not specified
Year:
2019
Region / City:
Wellington, New Zealand
Topic:
Colorectal cancer, chemotherapy regimens
Document type:
Draft definitions
Organization / Institution:
Ministry of Health, New Zealand
Author:
Ministry of Health
Target audience:
Medical oncologists, pharmacists, nurse specialists, other DHB staff
Period of validity:
Not specified
Approval date:
Not specified
Date of last modification:
Not specified
Note:
Year
Theme:
Healthcare, Oncology, Pharmaceutical Services
Document Type:
Agreement
Year:
2023
Region / City:
London, Norwich, Liverpool, UK
Topic:
Medical Research
Document Type:
Systematic Review with Meta-Analysis
Author:
Tristan D Boam, Melissa Gabriel, Rajeev Shukla, Paul D Losty
Target Audience:
Healthcare professionals, researchers in paediatric oncology
Period of Effect:
1990-2020
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
N/A
Region / City:
N/A
Topic:
Healthcare, Oncology, Nursing
Document Type:
Job Description
Organization:
Cherrybrook Cancer Services
Author:
N/A
Target Audience:
Healthcare professionals, Nurses
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2014
Region / city:
Not specified
Subject:
Mortality following palliative chemotherapy
Document type:
Audit report
Institution:
Not specified
Author:
Rafael Silverman
Target audience:
Clinical departments and healthcare professionals involved in palliative care and chemotherapy
Period of validity:
Not specified
Approval date:
Not specified
Last reviewed:
2 May 2024
Contextual description:
A departmental audit assessing short-term mortality rates following palliative chemotherapy for solid tumours in a specific time period.
Year:
2012
Region / City:
Europe / Vienna
Theme:
Lung Cancer, Oncology
Document Type:
Survey
Organization / Institution:
European Society for Medical Oncology (ESMO)
Author:
Dr. Raffaele Califano
Target Audience:
Medical Oncologists, Radiation Oncologists
Period of Action:
Deadline end of February 2012
Approval Date:
N/A
Date of Changes:
N/A
Document Title:
Intrathecal Chemotherapy (ITC) Prescription and Checklist
Appendix:
Appendix 5
Field:
Oncology
Medical Procedure:
Intrathecal chemotherapy administration
Document Type:
Medical prescription form and procedural checklist
Purpose:
Recording prescription, dispensing, transfer, and administration details for intrathecal chemotherapy
Healthcare Setting:
Hospital oncology department
Responsible Roles:
Prescriber, Clinical Pharmacy, Checking Nurse
Drugs Mentioned:
Methotrexate, Cytarabine, Hydrocortisone, Rituximab
Administration Route:
Intrathecal
Form Sections:
Patient details, prescription record, dispensing and transfer, administration record, verification checklist
Verification Requirements:
Patient identity confirmation, consent verification, drug and dose validation, pharmacy release confirmation
Safety Controls:
Drug verification, route confirmation, preparation date check, volume restriction, ITC register verification
Associated Procedure:
Lumbar puncture
Usage Frequency:
Single occasion prescription
Record Handling:
Copy to lead oncology pharmacist and original filed in patient notes
Document Type:
Supplementary tables from a clinical research publication
Medical Topic:
Neuroblastoma treatment and response assessment
Treatment Agent:
Hu14.18K322A monoclonal antibody
Therapy Phase:
Induction chemotherapy
Assessment Method:
Curie score imaging evaluation
Number of Patients:
43 patients (42 at end of induction assessment)
Infusion Protocol:
Planned 4-hour antibody infusion with possible extension to 8 or 16 hours based on patient tolerance and physician discretion
Infusion Duration Categories:
4 hours daily for 4 days; extended to 8 hours; extended to 16 hours
Clinical Measurements:
Median Curie scores and proportions of patients with CS > 0 and CS > 2
Assessment Timepoints:
Pretherapy; after 2 cycles of therapy; end of induction
Patient Withdrawal:
One patient withdrew after course 4 of therapy
Year:
Not specified
Region / City:
Not specified
Theme:
Oncology, Hematology
Document Type:
Scientific Research
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Action Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
International / Multicenter
Subject:
Breast cancer, Vitamin D, Neoadjuvant chemotherapy
Document type:
Supplemental material for research article
Institution / Organization:
Academic research institutions
Authors:
Not specified
Study population:
Patients with breast cancer undergoing neoadjuvant chemotherapy
Data sources:
Medline, Embase, Cochrane Library, Web of Science
Methods:
Literature search, data extraction, quality assessment, subgroup and sensitivity analyses, meta-analysis
Outcome measures:
Overall pathological response, pathological complete response (pCR), event-free survival (EFS)
Period covered:
Not explicitly stated, studies pooled from multiple cohorts
Supplementary content:
Tables of search strategy, data extraction, baseline characteristics, quality assessment; figures for bias, funnel plots, subgroup and sensitivity analyses, forest plots
Year:
2026
Patient Count:
21
Sex Distribution:
11 Males, 10 Females
Age Range:
30–72 years
Cytogenetic Alterations:
normal, t(10;13), del(15), -Y, t(8;21), inv(16), der(5)t(5;?), t(7;21), t(11;19), +11, +13, add(10), add(12), -16, -18, +2mar
Molecular Alterations:
FLT3-ITD, NPM1mutA, TP53
Induction Chemotherapy Regimens:
3+7, ICE, 3+7 +FLT3 inhibitor
Ex-vivo Treatment Groups:
Senescence High, Senescence Low
In-vivo Treatment Group:
chemotherapy-treated patients
Data Type:
Patient clinical and molecular dataset
Source:
Clinical study cohort
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Year:
2020
Region / City:
Elbonia
Meeting:
3GPP TSG-RAN WG2 #112
Document Type:
Technical report
Source / Organization:
Nokia, Nokia Shanghai Bell
Agenda Item:
5.4.3
Purpose:
Discussion and Decision
Scope:
Analysis of bandwidth combination sets (BWCS) for inter-ENDC and intra-ENDC configurations
Relevant Standards:
TS 38.101-1, TS 38.101-2, TS 38.101-3, TS 38.306
Deadline:
Short